Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alydyr, you said:
"What we do know, is that a promotional spamming campaign occurred..."
We do not know this at all. Weeks ago when you brought up this same claim, it was soundly disproven and rejected on this board.
LOL. I like it! :)
Personally, I feel the co has been diluting since the Fall when the sp rose so dramatically. That's for each of us to hypothesize until the 8K comes out. If true, I don't like it from a short-term perspective, but if it helps build the long-term business, I think it's appropriate. I'll let company managers decide what's in the best interest of long-term growth; they see the whole picture and we do not. They've done a great job so far in winning some major battles to get us to this point, so I'll trust that they have a grand plan that works really well into the future.
You can expect the s.p. for penny stocks to be volatile and manipulated even in the best of circumstances. What is expressed on this board is optimism about the promise of AEMD and where it looks to be headed in an industry changing area of medicine where it is, at this point, one of the leaders. IMO it's still going to be quite some time until that promise is realized, unless an agreement with one of the Bigs is consummated in the nearer term. So the "market" will do what it does in the meantime.
Great article, isn't it? I especially like these paragraphs:
Aethlon Medical (OTCBB: AEMD) is one of the only companies that may be able to participate in both diagnostics and therapeutics in the exosome space. The company recently announced the launch of Exosome Sciences (ESI) as a subsidiary that is advancing exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. Aethlon also attracted two of the best-known thought leaders in the exosome industry to play key roles in the new company.
"We are well positioned to benefit from the exosome revolution,” stated Aethlon Medical Chairman and CEO, Jim Joyce. "We are advancing patented first-in-class therapeutic technology to eliminate the presence of tumor-secreted exosomes that trigger the death of immune cells necessary for combating cancer. On the diagnostic front, our Exosome Sciences research team pioneered the field of exosome biology and is actively advancing a pipeline of next generation diagnostic tools".
Exactly. Major accumulation is going on here, and it's probably not with weak hands/penny ante traders that have come on board, since major blocks have been purchased over several months. The reality is, this stock is poised for a MAJOR move up in the near term--all IMO.
"IMHO, insiders are DUMPING this DECN like crazy and running circles around the small shareholders."
Alydyr, I know you stated the above as your opinion, but what evidence is your opinion based on? Can you show proof that insiders are selling shares, or is this just something you decided to "throw out there" just because you wanted to? Let us know, please!
Oh well.
Not sure why it's moving up, but I like it. I increased my long term position by 50% this week. Merry Christmas all!
I pretty much keep my shares locked up with gtc orders-have had them for some time, but this year have raised the sell price up quite a bit.
I've got mine for sale at $8, $10 and $22!
EVERYONE RUN AWAY FROM THIS DECN, THE SKY IS FALLING! LOL!
611,000 on the bid this morning.
Excellent post, Leirum! Gives credence to an uplist which should occur soon.
Thai, wouldn't you want to beat the others to the punch if you were, say, Medtronic, with a great opportunity to eventually jump to the forefront of the industry?
Could be a happy new year gift?!?!
"I equivocate about a tender offer from JnJ. If that scenario were to arise, will be intriguing how they arrive at a valuation. "
If even reasonably successful at selling Genstrip, DECN has tremendous leverage across the industry as the price leader. Add to that the new products coming on line in the future and you only increase that leverage.
I guess your answer on the "alleged" credit line is in the news today, right?
I agree with your statement:
Mr. Berman may be looking for a better time to entertain a buyout, like when they introduce additional products or when they have drawn blood against J&J in their own suit.
You could also add to your statement, in Mr. Berman's words, "if sales go through the roof...," and "When we uplist...."
Once these things start happening, the acquisition price goes much higher, especially with major players falling all over themselves to get market share, or avoid losing market share.
Things could get really interesting soon. All IMO. BTW, re. Mr. Berman, I vote chess player rather than poker.
With a 90 day period required to maintain sp above $1 before an uplist, I would say the price will be heading north soon.
It doesn't sound as if Mr. Berman is too interested in M&A talks with J&J or the other big 3....
"When we uplist, I think we'll get [M&A] interest," Berman said, adding that Decision would be open to considering a buyout "if the company that asked did not have Johnson & Johnson's habit of acquiring a company and then getting rid of everyone who works there, a common problem in M&A transactions involving large companies."
If Decision ends up hiring investment bankers to evaluate M&A opportunities in the future, Berman would want them to approach companies such as Medtronic Inc.and E.I. DuPont de Nemours and Co. Why? A takeover offer from the big four — J&J, Roche, Bayer, and Abbott — might raise antitrust concerns, he explained.
Thx KSk! You were born today to bring us this good news, huh? Much appreciated....
We'll need above a dollar for at least 90 days to uplist. It's coming, IMO.
Fufat, I can't access the company website either.
VF8, thanks so much for the excellent post! Gives an encouraging picture of where DECN is, and where we're probably headed in the next several months.
I bought into DECN over 4 years ago at more than $1/sh, and have averaged down so that I'm in the green now. May not take that long, but this one will make you glad you invested IMO. And hopefully $1 seems real cheap a year from now!
When you have a good company to invest in, don't be a fair weather investor, stick with it thru ups and downs. The uplist will not be complete for a while (late spring IMO) since it states that we want to uplist to the premium/premiere site. That will take 90 days with share price above $1.00. More work to be done first.
Great News!!
Decision Diagnostics' Board Votes to Uplist to OTC QX
Decision Diagnostics Corp. (OTCBB: DECN), the exclusive worldwide sales, service and regulatory processes agent for the popular Shasta GenStrip™, the unique Green Glucose Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan Ultra family of glucose testing meters, today announced that the company's Board of Directors has approved the company's uplisting to the OTC QX, the Premier OTC Market Tier. Concurrent with these Board Resolutions, the company has engaged a sponsoring brokerage and engaged counsel who shall serve as the company's Designated Advisor for Disclosure (DAD).
Keith Berman, Principal Executive Officer of Decision Diagnostics, commented, "The uplisting to the OTC QX is an activity we have considered for some time. Our ultimate goal is to achieve a listing on NYSE MKT (formerly NYSE Amex). However, the current uplist to the premier OTC market tier will accomplish the much needed goals of allowing our stock to be quoted and traded by a wider range of brokerages, particularly retail brokers, without many of the issues we endure as a fully reporting OTC BB company. We will have more to discuss about other aspects of this uplist registration in the coming days."
Interested parties may view the OTC QX web site:
http://www.otcqx.com/qx/otcqx/requirements
GenStrip™ test strips are a product of Shasta Technologies, LLC and are not manufactured, distributed, endorsed, or approved by nor associated with LifeScan®, Inc. a Johnson & Johnson® Company, manufacturers and distributors of the OneTouch® Ultra® Family of Meters and OneTouch® Ultra® test strips purchased prior to July 2013.
http://finance.yahoo.com/news/decision-diagnostics-board-votes-uplist-141500667.html
Good try pemo. Here's the scoop (historical bio) on Marcial from his own pen. Well respected positions in the financial press community over a number of years. I will put my confidence in someone like him who writes for a highly respected financial publication now (Forbes), since Forbes' excellent reputation is obviously on the line by having him/others on their staff. Your attempt to cast negative light on him seems to be par for the course you've followed with DECN for years.
"I wrote the Inside Wall Street column at Business Week Magazine for 28 years, through December 30, 2009. It was one of the most influential market columns as it moved stocks that I highlighted each week. BW had a yearly ScoreCard Report that tracked the performance of the stocks I mentioned, and the results confirmed their positive impact..I also wrote two books: “"http://www.amazon.com/Secrets-Street-Dark-Making-Money/dp/0070402566"Secrets of the Street, the Dark Side of Making Money,” published by McGraw-Hill in 1995, and “Gene Marcial’s Seven Commandments of Stock Investing,” published by FT Press in 2008. I resumed writing the “Inside Wall Street” column for AOL DailyFinance after Bloomberg acquired BW in December 2009. Subsequently, I moved the column to MSN.com after AOL merged with the Huffington Post. I then started writing for Forbes.com with a new column, “Street Beat,” in mid-April 2011, where I expect my readers will follow me.
Thanks to whoever posted the link to the most recent Forbes article!
Hey Alydyr, as moderator, would you please post the new Forbes article and link with the other Forbes articles at the top of the DECN IHUB page? That would be much appreciated from all interested in this company. TIA.
Why don't you let management handle it since I believe they have a little better info than you or I. How do you know who was in the focus groups? Do you think they had nobody who was diabetic? Their target audience is people with Lifescan meters, ie. wouldn't you figure that those people are diabetics and would have significant input re. the commercial spots?
"At what price point would these intersect?"
Double digits :)
diarch, I think you're correct. This ad is the first with more to come. This one gets the "hook" in with the jingle. The next ones define and sell the product. We have progressive revelation of Genstrip.
GLTY. I used to trade more, but now mostly buy and hold. I have several penny stocks that I think are industry changers if they ever make it. This one will not only make it, but will have such big rewards that none of the others will probably match it. We'll see. All IMO
It's hard to tell, but we should know something soon. If they don't acquire the company, someone else could, or DECN will do great on their own. BTW, congrats on making a very good investment!
Yes, the higher the acquisition price the higher the pps.
Mr S said recently in another post:
"My partner the IP attorney heard a rumor today. His information source told him that he was recently interviewed by Forbes for a big expose' due out before Thanksgiving. It is supposed to be the closure to all of the other articles written about DECN lately."
The last time Forbes wrote an article, was on Sep 11th. A lot of water has gone under the bridge since then-and the news has been very positive. In the previous article, the conclusion was as follows:
"An easy solution on this issue would be for J&J to resort to its active M&A strategy. With Decision’s low market capitalization, it wouldn’t be improbable to expect that J&J may just opt to gobble up Decision Diagnostics to add to its growing list of acquisitions. That way it would acquire Genstrip and get rid of both a competitive product and a potentially costly legal battle."
I wonder what the conclusion will be this time?
VF, nothing has come easy so far, so for you to say that it's smooth sailing ahead, there must be a knockout punch coming.
The proverbial calm before the storm!
IMO, filling the gap at .93. Could still close in the green today.